Zachary Davis

2.0k total citations
35 papers, 1.1k citations indexed

About

Zachary Davis is a scholar working on Immunology, Oncology and Virology. According to data from OpenAlex, Zachary Davis has authored 35 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Immunology, 20 papers in Oncology and 7 papers in Virology. Recurrent topics in Zachary Davis's work include Immune Cell Function and Interaction (30 papers), CAR-T cell therapy research (18 papers) and T-cell and B-cell Immunology (16 papers). Zachary Davis is often cited by papers focused on Immune Cell Function and Interaction (30 papers), CAR-T cell therapy research (18 papers) and T-cell and B-cell Immunology (16 papers). Zachary Davis collaborates with scholars based in United States, Sweden and Australia. Zachary Davis's co-authors include Jeffrey S. Miller, Martin Felices, Daniel A. Vallera, Edward Barker, Vicente Planelles, Jeffrey P. Ward, Todd Lenvik, Michael R. Verneris, Edward M. Campbell and Ankur H. Shah and has published in prestigious journals such as SHILAP Revista de lepidopterología, Blood and The Journal of Immunology.

In The Last Decade

Zachary Davis

32 papers receiving 1.1k citations

Peers

Countries citing papers authored by Zachary Davis

Since Specialization

Citations

This map shows the geographic impact of Zachary Davis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zachary Davis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zachary Davis more than expected).

Fields of papers citing papers by Zachary Davis

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Zachary Davis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zachary Davis. The network helps show where Zachary Davis may publish in the future.

Co-authorship network of co-authors of Zachary Davis

This figure shows the co-authorship network connecting the top 25 collaborators of Zachary Davis. A scholar is included among the top collaborators of Zachary Davis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Zachary Davis. Zachary Davis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The transcription factor BCL11B drives NK cell cytotoxicity and antitumor activity 2025 ·The Journal of Immunology ·Akhilesh Kumar, (unknown), (unknown), (unknown), Alexander J. Lenvik, Martin Felices, Zachary Davis, Laura E. Bendzick, (unknown), Yenan T. Bryceson, Jeffrey S. Miller, Frank Cichocki	0
2	iPSC-derived NK cells expressing high-affinity IgG Fc receptor fusion CD64/16A to mediate flexible, multi-tumor antigen targeting for lymphoma 2024 ·Frontiers in Immunology ·(unknown), Kristin M. Snyder, (unknown), (unknown), Zachary Davis, (unknown), (unknown), Bryan Hancock, Ryan Bjordahl, Martin Hosking, Jeffrey S. Miller, Bahram Valamehr, Jianming Wu, Bruce Walcheck	3
3	Advances in NK cell therapy for brain tumors 2023 ·npj Precision Oncology ·Jawad Fares, Zachary Davis, Julian S. Rechberger, (unknown), Jonathan Schwartz, David J. Daniels, Jeffrey S. Miller, Soumen Khatua	28
4	iPSC-derived natural killer cells expressing the FcγR fusion CD64/16A can be armed with antibodies for multitumor antigen targeting 2023 ·Journal for ImmunoTherapy of Cancer ·Kristin M. Snyder, (unknown), Zachary Davis, Martin Hosking, Geoffrey T. Hart, (unknown), (unknown), Ryan Bjordahl, Bryan Hancock, (unknown), Jeffrey S. Miller, Bahram Valamehr, Jianming Wu, Bruce Walcheck	13
5	SURG-09. TARGETING A SHARED GLIOBLASTOMA CELL STATE THROUGH ADAPTIVE NATURAL KILLER CELLS AUGMENTED WITH TRISPECIFIC KILLER CELL ENGAGER (TRIKE) IMMUNE-MODULATOR AGAINST CD276 2023 ·Neuro-Oncology ·Jianfang Ning, Zachary Davis, Shan Zhu, Jeffrey S. Miller, Clark Chen	1
6	755P B7H3-targeted tri-specific killer engagers deliver IL-15 to NK cells but not T-cells, and specifically target solid tumors as a pan-tumor antigen strategy mediated through NK cells 2022 ·Annals of Oncology ·Jeffrey S. Miller, Nicholas A. Zorko, (unknown), (unknown), (unknown), Peter K. Howard, (unknown), Zachary Davis, (unknown), (unknown), Martin Felices	8
7	The Effects of Body Mass Index on In-hospital mortality following first ischemic or hemorrhagic stroke events: Does the “obesity paradox” apply? 2021 ·Annals of Medicine and Surgery ·(unknown), (unknown), (unknown), (unknown), Zachary Davis, (unknown), Juan Gabriel Ruíz, (unknown), Adel Elkbuli	9
8	Low-density PD-1 expression on resting human natural killer cells is functional and upregulated after transplantation 2021 ·Blood Advances ·Zachary Davis, Martin Felices, Todd Lenvik, Sujan Badal, (unknown), Peter Hinderlie, James L. Riley, Daniel A. Vallera, Bruce R. Blazar, Jeffrey S. Miller	26
9	126P Novel B7-H3 targeting dual nanobody NK cell engagers display robust activity against a broad spectrum of solid and hematologic malignancies 2021 ·Annals of Oncology ·Nicholas A. Zorko, Martin Felices, Aimee Merino, Joshua M. Walker, Behiye Kodal, Alexander J. Lenvik, Zachary Davis, Todd Lenvik, (unknown), Yvette Soignier, (unknown), Peter Hinderlie, Emmanuel S. Antonarakis, Frank Cichocki, Jaiweon Hwang, G.E.L. van den Berk, Jeffrey S. Miller	4
10	Anti-NKG2C/IL-15/anti-CD33 killer engager directs primary and iPSC-derived NKG2C+ NK cells to target myeloid leukemia 2021 ·Molecular Therapy ·Emily Chiu, Martin Felices, Frank Cichocki, Zachary Davis, Hongbo Wang, (unknown), Daniel A. Vallera, Tom Lee, Ryan Bjordahl, Karl‐Johan Malmberg, Bahram Valamehr, Jeffrey S. Miller	35
11	Adaptive NK Cells Resist Regulatory T-cell Suppression Driven by IL37 2018 ·Cancer Immunology Research ·Dhifaf Sarhan, Keli L. Hippen, (unknown), (unknown), Xianghua Luo, Todd Lenvik, Julie Curtsinger, Zachary Davis, Bin Zhang, Sarah Cooley, Frank Cichocki, Bruce R. Blazar, Jeffrey S. Miller	93
12	Natural killer cells unleashed: Checkpoint receptor blockade and BiKE/TriKE utilization in NK-mediated anti-tumor immunotherapy 2017 ·Seminars in Immunology ·Zachary Davis, Daniel A. Vallera, Jeffrey S. Miller, Martin Felices	108
13	CD155 on HIV-Infected Cells Is Not Modulated by HIV-1 Vpu and Nef but Synergizes with NKG2D Ligands to Trigger NK Cell Lysis of Autologous Primary HIV-Infected Cells 2016 ·AIDS Research and Human Retroviruses ·Zachary Davis, (unknown), Andrew C. Cogswell, Jeffrey P. Ward, Vicente Planelles, Edward Barker	20
14	A Conserved HIV-1-Derived Peptide Presented by HLA-E Renders Infected T-cells Highly Susceptible to Attack by NKG2A/CD94-Bearing Natural Killer Cells 2016 ·PLoS Pathogens ·Zachary Davis, Andrew C. Cogswell, (unknown), (unknown), Julie Boucau, (unknown), Sylvie Le Gall, Vicente Planelles, Kerry S. Campbell, Edward Barker	60
15	Generation of BiKEs and TriKEs to Improve NK Cell-Mediated Targeting of Tumor Cells 2016 ·Methods in molecular biology ·Martin Felices, Todd Lenvik, Zachary Davis, Jeffrey S. Miller, Daniel A. Vallera	131
16	Natural Killer Cell Adoptive Transfer Therapy 2015 ·The Cancer Journal ·Zachary Davis, Martin Felices, Michael R. Verneris, Jeffrey S. Miller	91
17	Adaptive Natural Killer Cell and Killer Cell Immunoglobulin–Like Receptor–Expressing T Cell Responses are Induced by Cytomegalovirus and Are Associated with Protection against Cytomegalovirus Reactivation after Allogeneic Donor Hematopoietic Cell Transplantation 2015 ·Biology of Blood and Marrow Transplantation ·Zachary Davis, Sarah A. Cooley, Frank Cichocki, Martin Felices, (unknown), Xianghua Luo, Todd E. DeFor, Yenan T. Bryceson, Don J. Diamond, Claudio G. Brunstein, Bruce R. Blazar, John E. Wagner, Daniel J. Weisdorf, Amir Horowitz, Lisbeth A. Guethlein, Peter Parham, Michael R. Verneris, Jeffrey S. Miller	48
18	Preparation and Use of HIV-1 Infected Primary CD4+ T-Cells as Target Cells in Natural Killer Cell Cytotoxic Assays 2011 ·Journal of Visualized Experiments ·Zachary Davis, Jeffrey P. Ward, Edward Barker	11
19	Degranulation of Natural Killer Cells Following Interaction with HIV-1-Infected Cells Is Hindered by Downmodulation of NTB-A by Vpu 2010 ·Cell Host & Microbe ·Ankur H. Shah, (unknown), Zachary Davis, Jeffrey P. Ward, Edward M. Campbell, Vicente Planelles, Edward Barker	144
20	HIV-1 Vpr Triggers Natural Killer Cell–Mediated Lysis of Infected Cells through Activation of the ATR-Mediated DNA Damage Response 2009 ·PLoS Pathogens ·Jeffrey P. Ward, Zachary Davis, Jason L. DeHart, Erik S. Zimmerman, Alberto Bosque, Enrico Brunetta, Domenico Mavilio, Vicente Planelles, Edward Barker	118

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact